Brammer Bio formed through merger of Brammer Biopharmaceuticals and Florida Biologix
The merged company will combine deep technical expertise in process development and clinical manufacturing.
Brammer Biopharmaceuticals has announced its merger with Florida Biologix to create the best-in-class cell and gene therapy biologics contract development and manufacturing organization (CDMO). The merged company, Brammer Bio, will combine deep technical expertise in process development and clinical manufacturing with demonstrated capabilities, operating approaches and the quality standards required for commercial manufacturing. Ampersand Capital Partners, the majority shareholder of Florida Biologix, made an additional investment in the combined company and is the only institutional investor in Brammer Bio.
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications, along with process and analytical development, and regulatory support enabling large pharma and biotech clients to accelerate the delivery of novel medicines and improve patient health.
Brammer Bio occupies 45,000 ft2 of process development and Phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, Phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.
The management team is led by Mark Bamforth, President and CEO, and Steven Kasok, CFO, who were previously co-founders of Gallus Biopharmaceuticals, and Dr Richard Snyder, CSO, the founder of Florida Biologix, which was spun out of the University of Florida in 2015.
“There is a rich pipeline of over 500 cell and gene therapies in the clinic, and many of the large and specialist biotech companies pursuing these promising treatments want to leverage the expertise of a reliable, high-quality CDMO to supply their products for clinical through to commercial use. Brammer has the necessary laboratory and production capabilities and a highly skilled team of scientists with the development, manufacturing, and analytical expertise required to tackle the challenges posed by these novel technologies and help accelerate their transition from the clinic to patients in need. We are Manufacturing Personalized” Mark Bamforth, President and CEO, commented.
Brammer Bio, in combination with Florida Biologix, has a 10-year track record of providing development, clinical-phase manufacturing, and testing services, supporting clients with advanced therapeutic products and processes. Brammer intends to double the process development and early-clinical capacity at its Florida location, building on its robust clientele base. Existing and future clients taking their gene and cell therapy projects to phase III and beyond will be supported at the Lexington, MA facility.
“We recently began exploring options for gaining access to larger-scale manufacturing capabilities. With the deep manufacturing and commercial expertise, knowledge of facility design, and implementation of commercial quality and regulatory systems that Mark and Steven bring to the table, the marriage of Florida Biologix’s early client pipeline with Brammer Biopharmaceuticals is a perfect fit,” says Richard O. Snyder, Chief Scientific Officer for Brammer Bio.
David Anderson, Partner at Ampersand Capital Partners, said: "Having recently led the spin-out of Florida Biologix from the University of Florida, we are delighted to support this merger with Brammer Bio to create the leading company in its field with the expertise to support clients as their products advance into Phase III and towards licensure. The combination of Mark Bamforth and Steven Kasok with Richard Snyder creates a powerful team which will accelerate the growth of the business and expand the capacity to serve clients."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance